Dialectic Therapeutics develops targeted therapies using its proprietary Antiapoptotic Protein Targeted Degradation (APTaD™) technology to selectively induce cancer cell death by degrading the BCL-XL protein. This approach aims to provide effective treatment options for patients with advanced cancers who have limited or no available therapies, while minimizing toxicity and resistance.
Funding
$8.9M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many advanced cancers lack effective treatment options, leading to limited or no available therapies for patients. Current treatments often face challenges related to toxicity and the development of resistance, further complicating patient care.
Solution
Dialectic Therapeutics is developing targeted therapies using its Antiapoptotic Protein Targeted Degradation (APTaD™) technology to selectively induce cancer cell death. This approach focuses on degrading the BCL-XL protein, a key factor in cancer cell survival, to stimulate cell death or increase susceptibility to chemotherapy. The APTaD™ platform can be applied to other significant proteins associated with cancer that are currently difficult to target. DT2216, Dialectic's lead candidate, is currently in clinical trials as a single agent and in combination therapy for liquid and solid tumors.
Target Audience
The primary target audience includes patients with advanced cancers who have exhausted other treatment options, as well as oncologists and researchers seeking novel therapeutic approaches.
Features
- APTaD™ technology platform for targeted protein degradation
- DT2216 compound selectively degrades BCL-XL protein in cancer cells
- Demonstrated effectiveness in preclinical studies across various liquid and solid tumors, both as a single agent and in combination with chemotherapy
- Reduced likelihood of cancer cells developing resistance compared to traditional chemotherapy drugs
- Minimal toxicity, particularly to platelets, observed in preclinical studies
- Potential application to a broader range of BCL family proteins and other cancer-related targets